Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristics.

This retrospective study demonstrated that patients with advanced non-small cell lung cancer who experienced any-grade or grade 1-2 immune-related adverse events (irAEs) with immune checkpoint inhibitor plus chemotherapy (ICI+Chemo) as first-line treatment regimen had significantly longer progression-free survival (PFS;  < 0.001) and overall survival (OS;  < 0.05) compared with patients without any irAE. Three variables were identified as predictors of favorable PFS and OS: absence of baseline brain metastasis ( < 0.05), receiving first-line ICI+Chemo ( < 0.01), and occurrence of any grade adverse events ( < 0.001). Using these three variables, two nomograms were generated to predict PFS and OS, which were validated using two independent cohorts treated with Chemo or ICI+Chemo ( = 161) or ICI monotherapy ( = 109). Patients with low scores in discovery and validation cohorts consistently had significantly longer PFS ( < 0.001) and OS ( < 0.05) than those with high scores. Our findings provide preliminary evidence of the clinical utility of a nomogram in prognosticating ICI-treated patients.